Ike Swetlitz
Health Reporter at Bloomberg News
I don't check DM's; contact me here: https://t.co/M1WW3rdoWC Bloomberg @business health reporter in Boston. Previously: @SearchlightNM @statnews
Articles
-
1 day ago |
news.bloombergtax.com | Madison Muller |Robert Langreth |Ike Swetlitz
A new class of weight-loss drugs known as GLP-1s have proved to be game changers for people with obesity. They’re also minting billions of dollars for the pharmaceutical companies that developed them, Eli Lilly & Co. and Novo Nordisk A/S. The high prices for these drugs along with spotty insurance coverage have left them out of reach for many Americans. That’s beginning to change, however, as Lilly and Novo offer discounted versions to patients whose insurance doesn’t cover the medications.
-
1 day ago |
news.bloomberglaw.com | Madison Muller |Robert Langreth |Ike Swetlitz
A new class of weight-loss drugs known as GLP-1s have proved to be game changers for people with obesity. They’re also minting billions of dollars for the pharmaceutical companies that developed them, Eli Lilly & Co. and Novo Nordisk A/S. The high prices for these drugs along with spotty insurance coverage have left them out of reach for many Americans. That’s beginning to change, however, as Lilly and Novo offer discounted versions to patients whose insurance doesn’t cover the medications.
-
1 day ago |
bloomberg.com | Madison Muller |Robert Langreth |Ike Swetlitz
Wegovy and Zepbound have revolutionized the treatment of obesity. (Bloomberg Businessweek) -- A new class of weight-loss drugs known as GLP-1s have proved to be game changers for people with obesity. They’re also minting billions of dollars for the pharmaceutical companies that developed them, Eli Lilly & Co. and Novo Nordisk A/S. The high prices for these drugs along with spotty insurance coverage have left them out of reach for many Americans.
-
1 week ago |
bloomberg.com | Ike Swetlitz
A CVS pharmacy in Miami, Florida, US, on Tuesday, Oct. 1, 2024. CVS Health Corp. plans to cut roughly 2,900 jobs to reduce costs, the health-care company said, as it conducts a strategic review of its operations that includes a possible breakup. Photographer: Eva Marie Uzcategui/Bloomberg(Bloomberg) -- Activist investor Glenview Capital Management sold 3.75 million shares of CVS Health Corp. — about a third of its stake — and said it was pleased with recent changes at the health care conglomerate.
-
1 week ago |
crainsnewyork.com | Ike Swetlitz |Jonathan Randles
Less than a year after completing a restructuring that was supposed to turn the troubled pharmacy chain around, Rite Aid has filed for bankruptcy again. The company was unable to secure additional capital from lenders in order to continue operating the business, Chief Executive Officer Matthew Schroeder said in a letter to employees that was reviewed by Bloomberg News.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 3K
- Tweets
- 3K
- DMs Open
- Yes
Major US health insurer Anthem is demanding at least $1 million from health care providers for allegedly improper Ozempic prescriptions. Prescribers deny the allegations, and experts are scratching their heads at Anthem's behavior. Mine for @business: https://t.co/RSJSA8FCDa
News: @EliLillyandCo sent cease-and-desist letters demanding doctors stop selling and promoting compounded versions of Mounjaro and Zepbound made at state-licensed facilities. My story with @g0ingmad for @business: https://t.co/TSdyjuOkNs
RT @daveyalba: NEW with @ikeswetlitz: Google’s parent company spent billions on failed health projects. Will healthcare AI be its saving gr…